Exogenous administration of IGF-I in experimental liver fibrosis improved liver function [21], reduced oxidative damage [21, 22], provided mitochondrial protection [23] and limited fibrosis [24, 25, 30] in rodent species, suggesting potential clinical applications of IGF-I. Here, IGF1 is linked to Hepatic fibrosis.